Back

Evidence from normal human arteries: IRF7 triggers atherosclerosis by enhancing vascular smooth muscle cells inflammation

31 August 2025 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Molecular drivers of vascular remodelling: from atherosclerosis to aneurysm therapy Atherosclerosis, Cerebrovascular Diseases, Aneurysm, Restenosis ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Shuo Cheng

Nanjing University of Chinese Medicine, Nanjing (China)

7 More presentations in this session

Presentation thumbnail
PI3Ka protects against arteriosclerosis progression and plaque instability by controlling vascular smooth muscle cell functions
Doctor M. Zierden (Cologne, DE)
Abstract Slides Video
Presentation thumbnail
VasCraft: new decellularized and re-endothelialized human vascular graft produced by tissue engineering for use in arterial bypass
Mrs G. Iraola Picornell (Badalona, Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Dapagliflozin suppresses vascular smooth muscle cell senescence by promoting autophagy
Doctor H. Yang (Changsha, CN)
Abstract Slides Video
Presentation thumbnail
Mass spectrometry-based proteomics identifies high glucose-induced changes in vascular smooth muscle (VSMCs) and sustained extracellular signal-regulated kinases (ERK) activation
Mrs R. Aldahhasi (Leicester, GB)
Abstract Slides Video
Presentation thumbnail
MicroRNA-31-5p promotes vascular remodeling by modulating smooth muscle cell activity via STK40
Doctor K. Kalies (Halle, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Molecular drivers of vascular remodelling: from atherosclerosis to aneurysm therapy

The Event

Event poster

ESC Congress 2025

31 August 2025 10:15 CET
You may be interested in
thumbnail
Congress Session
Immune regulation and inflammatory drivers of atherosclerosis progression
thumbnail
Congress Session
Experimental studies in coronary atherosclerosis disease
thumbnail
Congress Presentation
Smooth muscle cells as therapeutic targets for plaque vulnerability

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources